The company leverages proprietary DNA methylation technology to develop non-invasive blood tests for cancer screening and monitoring across multiple cancer indications. Epigenomics competes in the emerging liquid biopsy market, positioning itself as a developer of diagnostic tests that enable earlier cancer detection through accessible blood sampling rather than more invasive procedures.
Cyborg Score Rationale
Epigenomics operates in a high-growth liquid biopsy market with validated technology and regulatory approvals. However, the company faces significant competitive pressure from well-funded diagnostics players and biotechs in the same space. Limited recent financial data and analyst coverage suggest execution and commercialization risks.
Top Insights
DNA methylation-based blood tests address a large market opportunity for non-invasive cancer screening
Epi proColon has regulatory approvals in multiple markets, positioning it for global commercialization
Competition from larger diagnostics companies and emerging liquid biopsy platforms requires strong execution
Success depends on reimbursement adoption and clinical evidence generation for pipeline indications
Named Competitors
Guardant Health platform — Liquid biopsy and circulating tumor DNA testing
Exact Sciences — Molecular diagnostics and early cancer detection
Foundation Medicine — Genomic profiling and liquid biopsy testing
Recent Developments
Company listed on London Stock Exchange (LSE: 0QXH) as of December 2020
Epi proColon commercialization ongoing across US, Europe, and China markets
Open the full interactive Epigenomics AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.